The National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program offers a grant opportunity for identifying small molecule or biologic lead compounds with therapeutic potential against chemical threats. This grant aims to support research on molecular target confirmation, in vitro and preliminary in vivo efficacy evaluations, ADME/Tox assessments, and PK/PD studies. The ultimate goal is to identify at least one lead compound ready for optimization to develop effective therapeutics against a range of chemical threats, including chemical warfare agents, industrial chemicals, pharmaceutical-based agents, and pesticides. Projects must include milestone-based translational study plans to advance compounds from Technical Readiness Level 1-3.
Opportunity ID: 309956
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-19-039 |
| Funding Opportunity Title: | Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 26, 2018 |
| Last Updated Date: | Oct 26, 2018 |
| Original Closing Date for Applications: | Sep 14, 2021 |
| Current Closing Date for Applications: | Sep 14, 2021 |
| Archive Date: | Oct 20, 2021 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) City or township governments For profit organizations other than small businesses Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public housing authorities/Indian housing authorities Special district governments County governments Small businesses Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA “CounterACT Optimization of Therapeutic Lead Compound (U01)” (PAR-18-NNN). The scope of this FOA encompasses Technical Readiness Level (TRL) 1-3 – see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-19-039.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00245902 | Aug 10, 2019 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00259484 | Aug 10, 2019 | Sep 14, 2021 | View |
Package 1
Mandatory forms
309956 RR_SF424_2_0-2.0.pdf
309956 PHS398_CoverPageSupplement_4_0-4.0.pdf
309956 RR_OtherProjectInfo_1_4-1.4.pdf
309956 PerformanceSite_2_0-2.0.pdf
309956 RR_KeyPersonExpanded_2_0-2.0.pdf
309956 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
309956 RR_Budget_1_4-1.4.pdf
309956 RR_SubawardBudget30_1_4-1.4.pdf
309956 PHS398_ModularBudget_1_2-1.2.pdf
309956 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
309956 RR_SF424_2_0-2.0.pdf
309956 PHS398_CoverPageSupplement_5_0-5.0.pdf
309956 RR_OtherProjectInfo_1_4-1.4.pdf
309956 PerformanceSite_2_0-2.0.pdf
309956 RR_KeyPersonExpanded_2_0-2.0.pdf
309956 PHS398_ResearchPlan_4_0-4.0.pdf
309956 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
309956 RR_Budget_1_4-1.4.pdf
309956 RR_SubawardBudget30_1_4-1.4.pdf
309956 PHS398_ModularBudget_1_2-1.2.pdf
309956 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
